Cristina R Ferrone
Overview
Explore the profile of Cristina R Ferrone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
318
Citations
14809
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bolm L, Nebbia M, Catalano O, Lionetto G, von Bresinsky J, Duhn J, et al.
Langenbecks Arch Surg
. 2025 Feb;
410(1):79.
PMID: 39982524
Background: To assess technical difficulty scores for laparoscopic liver resections (LLR) in a large well-characterized cohort of low to high difficulty LLR. Methods: Patients undergoing LLR and open liver resection...
2.
Sun Y, Maggs L, Panda A, Wright S, Cicerchia A, Jenney A, et al.
Cancer Immunol Res
. 2025 Jan;
13(2):210-228.
PMID: 39785827
Novel therapeutic strategies are needed to improve the efficacy of chimeric antigen receptor (CAR) T cells as a treatment of solid tumors. Multiple tumor microenvironmental factors are thought to contribute...
3.
Ventin M, Arya S, Cattaneo G, Fernandez-Del Castillo C, Wei A, Zureikat A, et al.
Ann Surg
. 2025 Jan;
PMID: 39781747
Objective: To investigate the clinicopathological features and long-term outcomes of cystic and solid pancreatic neuroendocrine tumors (PanNETs). Summary Background Data: PanNETs uncommonly present as cystic lesions. Whether cystic PanNETs represent...
4.
Petruch N, Bolm L, Nebbia M, Arya S, Ventin M, Qadan M, et al.
Anticancer Res
. 2024 Dec;
45(1):189-199.
PMID: 39740812
Background/aim: Predictors of recurrence following resection of hepatocellular carcinoma (HCC) are not fully established. This study investigated potential risk factors and prognostic scores for this situation. Patients And Methods: In...
5.
Cloyd J, Sarna A, Arango M, Bates S, Bhutani M, Bloomston M, et al.
JAMA Surg
. 2024 Dec;
160(2):172-180.
PMID: 39630427
Importance: Neoadjuvant therapy (NT) is an increasingly used treatment strategy for patients with localized pancreatic ductal adenocarcinoma (PDAC). Little research has been conducted on cancer care delivery during NT, and...
6.
Dimitrieva S, Harrison J, Chang J, Piquet M, Mino-Kenudson M, Gabriel M, et al.
Cancer Res Commun
. 2024 Nov;
4(12):3049-3066.
PMID: 39485038
Pancreatic cancer remains a high unmet medical need. Understanding the interactions between stroma and cancer cells in this disease may unveil new opportunities for therapeutic intervention.
7.
Bao Q, Ventin M, DellAtti L, Tripepi M, Frigerio I, Butturini G, et al.
Pancreatology
. 2024 Oct;
24(7):1107-1114.
PMID: 39353845
Background: The impact of chemoradiotherapy on pathologic response, resection margin, and survival benefit is still debated. The aim of this study was to compare the rate of pathologic complete response...
8.
Lu C, Pankaj A, Raabe M, Nawrocki C, Liu A, Xu N, et al.
Hepatol Commun
. 2024 Sep;
8(10).
PMID: 39330965
Background: HCC is a highly vascular tumor, and many effective drug regimens target the tumor blood vessels. Prior bulk HCC subtyping data used bulk transcriptomes, which contained a mixture of...
9.
Perrotta G, Mohamed G, Larson B, Osipov A, Ferrone C, Lo S, et al.
JAMA
. 2024 Sep;
332(13):1108-1110.
PMID: 39235802
No abstract available.
10.